← Back to all trials
Recruiting
NCT04855656
Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors
Conditions: Advanced Solid Tumor
Sex: All
Ages: 12 Years – N/A
Healthy volunteers: No
Phase: PHASE1
Enrollment: 464
Sponsor: Debiopharm International SA
Location: # 1019, UCLA, Westwood Cancer Center Los Angeles California
Summary
The primary purpose of this study is to assess the safety and tolerability of lunresertib alone and in combination with RP-3500 or in combination with Debio 0123 in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.
Eligibility Criteria
Inclusion Criteria:
* Male or female and ≥12 years-of-age at the time of informed consent.
* Lansky performance status ≥50% for patients ≤16 years of age, or ECOG score of 0, 1, (or 2 for module 1) for patients \>16 years of age.
* Locally advanced or metastatic resistant or refractory solid tumors.
* Patients \
Source: ClinicalTrials.gov (NCT04855656). StuddyBuddy aggregates publicly available trial information.
